Top Scientists Leading
Tomorrow's Treatments

Ymmunobio is committed to developing preclinical breakthroughs toward improving how cancer therapies are developed.

 

Dr. Katrin Rupalla founded Ymmunobio in 2021 as a way to advance developments in CEACAM1 and NPTXR research. Since that time, Dr. Rupalla has assembled a distinguished team of scientific and clinical leaders who are united in transforming how cancer and autoimmune diseases are treated.